Skip to content

US · XAIR · MEDICAL - DEVICES

Beyond Air, Inc. (XAIR) intrinsic value and stock valuation

$1.54as of 2026-11-21 · Mkt cap 3.86M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Beyond Air, Inc. DCF and intrinsic value

InvestorsCraft values XAIR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XAIR’s statements →

Beyond Air, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Garden City, NY 11530 beyondair.net

How the business is doing

Fiscal 2013–2026, USD

Revenue
$7.68M+54.6% 5y CAGRd
20132026
Net income
-$-33.25M
20132026
Free cash flow
-$-19.17M
20132026
Total equity
$6.21M-27.2% 5y CAGRd
20132026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2026, USD
20262025202420232022
Revenue$7.68M$3.71M$1.16M$0.00$0.00
Operating income-$-29.04M-$-44.54M-$-63.01M-$-52.06M-$-40.71M
Net income-$-33.25M-$-46.62M-$-60.24M-$-55.82M-$-43.18M
EPSd-$-79.17M-$-274.24M-$-753M-$-797.43M-$-719.67M
Operating cash flow-$-18.14M-$-38.22M-$-56.02M-$-33.01M-$-23.13M
Capital expenditure-$-1.02M-$-5.88M-$-5.75M-$-3.88M-$-1.38M
Free cash flow-$-19.17M-$-44.1M-$-61.76M-$-36.89M-$-24.51M
Total assets$35.4M$30.1M$57M$68.8M$99.2M
Total debt$23.4M$11.7M$17.8M$3.59M$3.49M
Net debt$16.6M$7.02M$6.46M-$-25.57M-$-76.75M
Total equity$6.21M$14.3M$27.2M$42M$78.2M
Cash and short-term investments$11.6M$6.92M$34.5M$45.9M$80.2M
Income statement
20262025202420232022
Revenue$7.68M$3.71M$1.16M$0.00$0.00
Cost of revenue$7.43M$5.37M$2.47M$560K$0.00
Gross profit$250K-$-1.66M-$-1.31M-$-560K$0.00
Research and development expenses$10.2M$16.9M$24.4M$16.8M$11.8M
Selling, general and administrative expenses$19.1M$26M$37.3M$34.7M$18.9M
Other expenses$0.00$0.00-$0.00$0.00$10M
Operating expenses$29.3M$42.9M$61.7M$51.5M$40.7M
Cost and expenses$36.7M$48.2M$64.2M$52.1M$40.7M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$3.52M$3.02M$2.91M$30K$780K
Depreciation and amortization$3.65M$3.57M$2.35M$1.17M$590K
Ebitda-$-27.17M-$-41.89M-$-59.03M-$-58.2M-$-42.7M
Operating income-$-29.04M-$-44.54M-$-63.01M-$-52.06M-$-40.71M
Total other income/expenses, net-$-5.29M-$-3.94M-$-1.29M-$-7.34M-$-3.35M
Income before tax-$-34.33M-$-48.48M-$-64.3M-$-59.4M-$-44.06M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-33.25M-$-46.62M-$-60.24M-$-55.82M-$-43.18M
Weighted average shares outstanding$420K$170K$80K$70K$60K
Weighted average diluted shares outstanding$420K$170K$80K$70K$60K
Balance sheet
20262025202420232022
Cash and short-term investments$11.6M$6.92M$34.5M$45.9M$80.2M
Net receivables$1.19M$860K$550K$650K$600K
Inventory$1.41M$2.42M$2.13M$1.13M$350K
Total current assets$24.8M$16M$43.9M$59.4M$92.9M
Property, plant and equipment, net$9.44M$12.7M$11.5M$7.5M$4.21M
Goodwill and intangible assets$1.02M$1.22M$1.43M$1.63M$1.84M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10.6M$14M$13M$9.34M$6.25M
Total assets$35.4M$30.1M$57M$68.8M$99.2M
Accounts payable$2.42M$1.95M$1.95M$2.02M$1.13M
Short-term debt$720K$1M$1.22M$1.15M$1.21M
Deferred revenue$0.00$0.00$140K$16.6M$8.37M
Total current liabilities$6.51M$5M$11.6M$19.8M$10.7M
Long-term debt$22.7M$10.7M$16.6M$2.44M$2.28M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.7M$10.7M$18.2M$6.94M$10.3M
Capital lease obligations$1.34M$1.88M$2.32M$2.7M$2.36M
Total liabilities$29.2M$15.7M$29.8M$26.7M$21M
Common stock$0.00$10K$10K$0.00$0.00
Retained earnings-$-319.57M-$-286.32M-$-239.7M-$-179.46M-$-123.64M
Accumulated other comprehensive income (loss)$130K-$-60K-$-10K$50K$100K
Total equity$6.21M$14.3M$27.2M$42M$78.2M
Total investments$4.9M$2.25M$23.1M$16.7M$0.00
Total debt$23.4M$11.7M$17.8M$3.59M$3.49M
Net debt$16.6M$7.02M$6.46M-$-25.57M-$-76.75M
Cash flow statement
20262025202420232022
Net income-$-33.25M-$-48.48M-$-60.24M-$-59.4M-$-43.18M
Depreciation and amortization$3.44M$3.57M$2.35M$1.17M$590K
Stock-based compensation$5.28M$9.15M$0.00$19.6M$0.00
Change in working capital$2.35M-$-6.15M-$-16.04M$5.39M$11.8M
Accounts receivable-$-470K-$-390K$100K-$-100K$100K
Inventory$1.11M-$-470K-$-1M-$-780K$0.00
Accounts payable$270K$400K-$-470K$840K-$-330K
Net cash provided by operating activities-$-18.14M-$-38.22M-$-56.02M-$-33.01M-$-23.13M
Investments in property, plant and equipment-$-1.02M-$-5.88M-$-5.75M-$-3.88M-$-1.38M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-3.67M$14.9M-$-12.23M-$-20.59M-$-1.45M
Common stock issued$16.3M$23M$28.2M$3.71M$79M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$29.1M$16.7M$43.2M$2.7M$79.5M
Net change in cash$7.47M-$-6.71M-$-27.68M-$-50.94M$55M
Cash at end of period$12.4M$4.9M$11.6M$36.8M$90.2M
Operating cash flow-$-18.14M-$-38.22M-$-56.02M-$-33.01M-$-23.13M
Capital expenditure-$-1.02M-$-5.88M-$-5.75M-$-3.88M-$-1.38M
Free cash flow-$-19.17M-$-44.1M-$-61.76M-$-36.89M-$-24.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Beyond Air, Inc.

        Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.

        CEO
        Robert Goodman
        Employees
        54
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Beyond Air, Inc. (XAIR)?

        InvestorsCraft does not currently publish an intrinsic value for XAIR. How the IC value is calculated.

        Is XAIR undervalued?

        InvestorsCraft does not publish an undervaluation signal for XAIR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.